VR Collaboration System to Improve Mental Health Outcomes
NCT ID: NCT05773131
Last Updated: 2023-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
566 participants
INTERVENTIONAL
2023-03-07
2024-03-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Virtual Reality Stimulation to Enhance Cognitive Function of Intensive Care Unit Patients
NCT03025373
Immersive Virtual Reality in Mechanically Ventilated Patients
NCT03569358
The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19
NCT04505761
AR Training Platform at Home
NCT05627050
Patient Experiences With Virtual Reality Mindfulness Skills Training
NCT05291533
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Methods and Materials: This single-blind, randomized, controlled trial will be conducted from January to December 2023 in the ICU of Peking Union Medical College Hospital (PUMCH). We aim to randomize 566 adult ICU patients with an expected mechanical ventilation time over 24 hours into the VRCS intervention group and the control group (283 in each group). The patients in the VRCS group can see their families in a virtual natural forest environment through VR headsets and communicate with them through an eye-tracking interaction method. Simultaneously, their family members can see and communicate with the patients through smartphones, computers, or TVs at home. The primary objective is to study the effect of VRCS on the mental health and hospitalization experience of MV patients during the ICU stay. The secondary outcome is to assess the effect of VRCS on the incidence of delirium and the quality of patient-family communication during hospitalization.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VR collaborative visualization group
In this intervention system, the stimulation materials, communication interface, collaboration tasks, and immersive 360-degree scenario will be played inside a commercially available head-mounted display on the patient side, as well as these materials will be played in the smartphone on the family members' side.
VR collaborative visualization system
Patients wear virtual reality head-mounted displays while family members using smart phones to interact in a same virtual space.
Standard ICU Care
Patients will be treated with standard ICU care and not receive VR stimulation.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VR collaborative visualization system
Patients wear virtual reality head-mounted displays while family members using smart phones to interact in a same virtual space.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years old, no upper age limit;
* Language: Chinese;
* RAAS score ≥ -2 points;
* Hemodynamic stability.
Exclusion Criteria
* Cognitive and consciousness impairment;
* Head trauma or surgery resulting in an inability to wear HMDs.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking Union Medical College Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yun Long, MD
Role: STUDY_DIRECTOR
Peking Union Medical College
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
PUMC
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JS-3575-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.